China's State FDA Approves Third H1N1 Flu Vaccine
This article was originally published in PharmAsia News
Executive SummaryBeijing Tiantan Biological products received clearance from the Chinese government for its vaccine against the H1N1 flu virus
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.